ExonHit Therapeutics Expands Strategic Alliance with Allergan
The parties' collaboration, which was initiated in 2003, has lead to a number of promising discovery programs at various stages of preclinical studies, with its most advanced compound currently finalizing preclinical development.
Under the terms of the collaboration, ExonHit receives financial support in the form of on-going R&D payments as well as payments for drug candidates achieving certain development milestones. Additionally, ExonHit will receive co-development and co-commercialization options in therapeutic areas outside of Allergan's key strategic areas, as well as, royalties or, in cases of co-development and co-commercialization, profit-sharing on commercialized drugs.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.